KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash from Investing Activities (2016 - 2025)

Acadia Pharmaceuticals has reported Cash from Investing Activities over the past 16 years, most recently at -$55.9 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at -$55.9 million for Q4 2025, down 145.74% from a year ago — trailing twelve months through Dec 2025 was -$302.6 million (down 890.78% YoY), and the annual figure for FY2025 was -$302.6 million, down 890.78%.
  • Cash from Investing Activities for Q4 2025 was -$55.9 million at Acadia Pharmaceuticals, up from -$79.4 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for ACAD hit a ceiling of $192.5 million in Q1 2023 and a floor of -$194.3 million in Q2 2023.
  • Median Cash from Investing Activities over the past 5 years was -$17.5 million (2021), compared with a mean of -$14.9 million.
  • Biggest five-year swings in Cash from Investing Activities: surged 35301.73% in 2024 and later tumbled 783.6% in 2025.
  • Acadia Pharmaceuticals' Cash from Investing Activities stood at $71.5 million in 2021, then tumbled by 124.81% to -$17.7 million in 2022, then surged by 98.04% to -$347000.0 in 2023, then surged by 35301.73% to $122.2 million in 2024, then crashed by 145.74% to -$55.9 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$55.9 million (Q4 2025), -$79.4 million (Q3 2025), and -$43.3 million (Q2 2025) per Business Quant data.